We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Intelligent Ultrasound Group Plc | IUG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.75 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.75 | 10.75 | 10.75 | 10.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 31/7/2024 06:28 by bamboo2 31 July 2024Intelligent Ultrasound Group plc (the "Group" or the "Company") Notice of results Analyst and investor briefing Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces it will issue its interim results for the six months ended 30 June 2024 on Wednesday, 14 August 2024. A briefing for analysts will be held via video call on 14 August 2024 at 09:30am BST. To register, please contact intelligentultrasoun The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 14 August 2024 at 11:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 13 Aug 2024, 09:00am BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet the Company via: Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited. |
Posted at 21/7/2024 17:09 by bamboo2 UK InvestorIntelligent Ultrasound (LON: IUG) is selling its Clinical AI operations to GE. The payment will be £40.5m. So far, £12.2m has been invested in the development of AI. The consideration is equivalent to 12.4p/share. This deal does not include the NeedleTrainer and NeedleTrainer Plus products or the simulation business. The remaining business had annual revenues of £10m last year. Lower simulation sales meant that the latest interim revenues fell from £6.1m to £5.3m. That includes £1.5m from Clinical AI, compared with £2m for the whole of the previous year. There are plans to return a substantial amount of this cash to investors. The share price jumped 44.8% to 10.5p. |
Posted at 17/7/2024 22:37 by 40 fathoms Not sure I have an answer to why healthcare professionals do not buy IUG stock.My guess is it is probably a combination of the difference between how US and UK doctors are paid (both in quantum but also their pension arrangements) and the fact that it a fact that the UK population at large are not natural equity investors. Funds maybe a bit, single stock positions absolutely not. We are so property obsessed and property is so tax advantaged that I can not see this changing meaningfully anytime soon. |
Posted at 11/7/2024 22:35 by bamboo2 New date confirmedGE HealthCare to announce second quarter 2024 results on July 31, 2024 CHICAGO--(BUSINESS WIRE)--Jul. 8, 2024-- GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. |
Posted at 05/7/2024 07:08 by bamboo2 Investigating this further.40F/anyone, I think this could have a significant effect on IUG, particularly if Phil Rackliffe wants to make symbolic changes. Let's hope the effect is positive. ==================== PRESS RELEASES GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers Jun 10, 2024 Roland Rott, the current president and CEO of Ultrasound, will lead Imaging, replacing Jan Makela Philip Rackliffe, the current president and CEO of Image Guided Therapies (IGT), will lead Ultrasound and IGT CHICAGO — June 10, 2024 — GE HealthCare (Nasdaq: GEHC) announced today that it has named Roland Rott president and CEO of Imaging and Phil Rackliffe president and CEO of Ultrasound and IGT. Both leaders bring to their roles decades of deep experience in healthcare innovation and experience leading global teams in businesses of scale. This also highlights the depth of internal talent that GE HealthCare is building to strengthen focus on delivering for patients and customers. These changes will be effective July 1, 2024. IGT, a $1.6 billion subsegment of Imaging, will be combined with the Ultrasound segment in the third quarter of 2024, to form a global business with more than $5.0 billion in annual revenue. [i] GE HealthCare is aligning IGT with Ultrasound to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. Aligning IGT and Ultrasound positions GE HealthCare to be more agile and address future imaging needs using these real-time modalities in both inpatient and outpatient settings. Without IGT, Imaging will remain GE HealthCare’s largest segment with more than $8.9 billion in annual revenue.[ii] This segment will enhance focus on solutions centered on surgical and interventional procedures, particularly interventional cardiology and structural heart, while continuing Ultrasound’s diagnostic leadership. Peter Arduini, chief executive officer of GE HealthCare, said, “Roland and Phil will bring fresh viewpoints, global perspective, and deep industry expertise to our Imaging segment and new Ultrasound and IGT segment. Elevating leaders who have a deep understanding of our customers’ needs, market trends, and our strategic focus will help enable us to accelerate innovation and growth. Roland and Phil are proven leaders who are well positioned to take on these new opportunities, drive our precision care strategy, and deliver for patients and customers.” Roland joined GE Healthcare in 2011 and has held multiple leadership roles within Ultrasound, ultimately becoming president and CEO in 2021. He has a strong track record of growing healthcare businesses at scale, and driving digital and artificial intelligence (AI) in product innovation. He has been instrumental in leading M&A activities including the BK Medical and Caption Health acquisitions, and established strategic alliances with new partners, such as the Bill & Melinda Gates Foundation and BARDA and Novo Nordisk. He has delivered significant platforming results in Ultrasound including the recently launched LOGIQ E10 Series and LOGIQ Fortis and Voluson Signature ultrasound systems, and will drive similar platforming efforts in Imaging. Before joining GE HealthCare, Roland worked as an executive committee member at a publicly traded company and founded two software companies that were acquired by strategic investors. Phil joined GE HealthCare in 2022 to lead IGT and has delivered significant accretive revenue growth for the business during his tenure. Since joining GE HealthCare, Phil has led R&D expansion related to new product introductions including Allia Pulse, 3DStent, EmboAssist AI and OmnifyXR. He has also led strategic equity investments focused on improving visualization and surgical navigation techniques using technology such as augmented reality during minimally invasive procedures. He has over two decades of global experience in MedTech, Medical Devices and Pharmaceuticals working for public companies, including Baxter Healthcare, Boston Scientific, and Pfizer, as well as Ernst and Young. Phil’s last role before joining GE HealthCare was CEO of Centerline Biomedical, a spinout of Cleveland Clinic. GE HealthCare expects to provide recast financial results to reflect the movement of IGT from Imaging to the new Ultrasound and IGT segment in its filings with the U.S. Securities and Exchange Commission for third quarter 2024. [i] All stated revenues for IGT, Ultrasound and Imaging are 2023 figures. [ii] All stated revenues for IGT, Ultrasound and Imaging are 2023 figures. |
Posted at 14/6/2024 12:25 by 40 fathoms @gsbmba99 - you are absolutely correct, it is indeed Interactive Investor not Interactive Brokers. IB are on the register but with only a small holding. I have corrected this in my previous post in order to avoid confusion. Thank you. |
Posted at 14/6/2024 12:13 by gsbmba99 Are we sure the leading seller is Interactive Brokers (the US listed company) and not Interactive Investor (ii.co.uk, a subsidiary of Abrdn)? Interactive Brokers seems a strange place to be holding IUG shares. The ability to trade SETSqx is pretty limited (auctions only?) and SEAQ is, I think, non-existent. |
Posted at 19/4/2024 06:07 by bamboo2 Notice of resultsAnalyst and investor briefing Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces it will issue its audited final results for the year ended 31 December 2023 on Wednesday, 1 May 2024. A briefing for analysts will be held via Teams on 1 May 2024 at 9.30am. To register, please contact intelligentultrasoun The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 1 May at 1pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet the Company via: Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited. |
Posted at 03/8/2023 06:35 by bamboo2 Intelligent Ultrasound Group PLC03 August 2023 Intelligent Ultrasound Group plc (the "Group" or the "Company") Notice of results Analyst and investor briefing Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces it will issue its interim results for the six months ended 30 June 2023 on Thursday, 17 August 2023. A briefing for analysts will be held via video call on 17 August 2023 at 9.30am. To register, please contact intelligentultrasoun The Company will host a live presentation for investors given by Stuart Gall and Helen Jones via the Investor Meet Company platform on Thursday, 17 August 2023 at 5pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet the Company via: Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited. |
Posted at 15/3/2023 08:13 by bamboo2 Notice of resultsAnalyst and investor briefing Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces it will issue its preliminary results for the year ended 31 December 2022 on Thursday, 20 April 2023. A briefing for analysts will be held via Zoom on 20 April 2023 at 9.30am. To register, please contact Walbrook PR at intelligentultrasoun The Company will host a live presentation for investors given by Stuart Gall and Helen Jones via the Investor Meet Company platform on Thursday, 20 April 2023 at 2.15pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet the Company via: Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited. Separately, the Company announces an investor day at their headquarters in Cardiff. This will take place on Tuesday, 25 April 2023 and will include an overview of the business and a live demonstration of the products. For further details and to register to attend, please contact cenkosir@cenkos.com or call 020 7397 8900. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
